Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15688-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#15688-1-AP, RRID:AB_2098171
- Product name
- ERCC6L antibody
- Antibody type
- Polyclonal
- Description
- ERCC6L antibody (Cat. #15688-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references IGF2BP2 promotes ovarian cancer growth and metastasis by upregulating CKAP2L protein expression in an m(6) A-dependent manner.
PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.
Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells.
Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.
Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1.
ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
ERCC6L promotes cell growth and invasion in human colorectal cancer.
Shi Y, Xiong X, Sun Y, Geng Z, Chen X, Cui X, Lv J, Ge L, Jia X, Xu J
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023 Oct;37(10):e23183
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023 Oct;37(10):e23183
PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.
Ye H, Shi W, Yang J, Wang L, Jiang X, Zhao H, Qin L, Qin J, Li L, Cai W, Guan J, Yang H, Zhou H, Yu Z, Sun H, Jiao Z
Cancer research 2023 Nov 15;83(22):3767-3782
Cancer research 2023 Nov 15;83(22):3767-3782
Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells.
Li C, Shi J, Wei S, Jia H
European journal of medical research 2023 Nov 15;28(1):517
European journal of medical research 2023 Nov 15;28(1):517
Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.
Huang X, Jiang L, Lu S, Yuan M, Lin H, Li B, Wen Z, Zhong Y
Oncology reports 2022 Jul;48(1)
Oncology reports 2022 Jul;48(1)
Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1.
Zu ML, Duan Y, Xie JB, Qi YS, Xie P, Borjigidai A, Piao XL
Journal of ethnopharmacology 2021 Jun 12;273:114017
Journal of ethnopharmacology 2021 Jun 12;273:114017
ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H, Wang H, Yu X, Zhou S, Zhang Y, Wang Z, Huang S, Wang Z
BMC cancer 2020 Sep 5;20(1):853
BMC cancer 2020 Sep 5;20(1):853
ERCC6L promotes cell growth and invasion in human colorectal cancer.
Xie Y, Yu J, Wang F, Li M, Qiu X, Liu Y, Qi J
Oncology letters 2019 Jul;18(1):237-246
Oncology letters 2019 Jul;18(1):237-246
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ERCC6L antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ERCC6L. This antibody recognizes human,mouse,rat antigen. The ERCC6L antibody has been validated for the following applications: ELISA, WB analysis.
